Journal of biomolecular structure & dynamics · 2020
Discovery of potent Camkk1 kinase inhibitors through e-pharmacophore and molecular screening approaches.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prajisha Jayaprakash, Biswal Jayashree, Jeyakanthan Jeyaraman
Аннотация
Diabetes is recognized as a major health problem and according to WHO estimates global prevalence of diabetes is expected to increase from 171 million in 2000 to 366 million in 2030, among which 21.7% will be Indians. The chronic nature of diabetes leads to several metabolic complications like kidney failure, cardiac problems and hypertension, etc.Camkk family members are attractive and emerging targets for the development of anti-diabetic drugs. However, the selectivity of inhibitors is a crucial property as a lack of selectivity could lead to serious adverse effects. STO-609 recently reported the role of Camkks a as potent inhibitor. In this study, Combined Molecular Docking and Pharmacophore Mapping were employed to identify potent lead molecules. E-Pharmacophore based virtual screening was performed against commercially available databases to identify the best lead molecule which was docked with the targets and analyzed for the binding pattern. Also, ADME and density function theory (DFT) studies of the compound were performed and the hits that showed good binding to the active sites and that matched with the pharmacophore models were considered as possible functional molecules against Camkk1. The results from e-pharmacophore based virtual screening and MD simulations evidenced that the top three compounds namely (Lifechemicals_1, Zinc_0910993 and Binding_10131) will be a promising inhibitor for Camkk1 family.Communicated by Ramaswamy H. Sarma.